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Since 1971, 21 placebo-controlled studies have been made to establish whether vitamin C
at a dosage of  ?1 g/day affects the common cold. These studies have not found any
consistent evidence that vitamin C supplementation reduces the incidence of the common cold
in the general population. Nevertheless, in each of the 21 studies, vitamin C reduced the
duration of episodes and the severity of the symptoms of the common cold by an average of 23%.
However, there have been large variations in the benefits observed, and clinical significance
cannot be clearly inferred from the results. Still, the consistency of the results indicates that the
role of vitamin C in the treatment of the common cold should be reconsidered.
INTRODUCTION
There has been a long-standing controversy about whether vitamin C is effective against
the common cold. From 4 placebo-controlled studies carried out before 1971, Pauling
concluded that vitamin C reduces the incidence and severity of the common cold (1, 2).
The greatest benefit was observed by Ritzel (3, 4), who used the largest dose (1 g/day).
This led Pauling to propose such amounts for the prevention and treatment of the
common cold. Pauling's claims were not generally accepted, yet they inspired a number
of intervention studies to determine whether vitamin C has any actual effect.
 In the present study the placebo-controlled studies published since 1971 in which
at least 1 g/day of vitamin C has regularly been given to test subjects are briefly
reviewed. If vitamin C has any effect on the incidence of, or morbidity due to, the
common cold it should be observed most clearly in these studies. Moreover, these
studies test whether Pauling's conclusions (1, 2) were correct, since none of the studies
on which his claims were based are included.
MATERIALS AND METHODS
The literature was thoroughly searched to find all placebo-controlled studies published since 1971, in which
at least 1 g/day of vitamin C had been regularly given to the study subjects. The search of the literature consisted
of several database searches using various search strategies (SCISEARCH, EMBASE, MEDLINE) and inspection
of the reference lists of all relevant articles and reviews. 18 publications (5-22) and 1 correction (23) were found,
describing studies falling under the specifications of the search. Two other extensive literature searches of "vitamin C
and the common cold" have also been carried out previously (21, 24). The studies found by this author are consistent
with the studies found in the 2 other literature searches (21, 24).
 The data shown in Fig. 1 are derived from 18 publications (5-22), 3 of which contain results with 2 vitamin groups
(9, 10, 17). Thus, the total number of vitamin groups has been 21. For a concise summary of the original results,
see Table I in ref. 25. The total number of subjects in the studies has been 6,600. All studies except 1 (6) were
double-blind. Some of the placebo groups were given 10-70 mg/day of vitamin C to ensure that the effects of
the larger doses were not due to alleviation of dietary deficiency (17, 19, 21). The group of twins living together in
the study by Carr et al. (19) has not been included, for reasons previously discussed (25). The D-ascorbic acid group
in the study by Clegg and Macdonald (12) is not included, even though a benefit from the D-isomer was observed, since
the physiological form of vitamin C is L-ascorbic acid. Some studies have used several parameters to quantify
the duration of the episode or the severity of the symptoms (25). As regards alternative outcome parameters,
days off from work, absence from school, days in bed (5, 16, 17), general malaise and fever (11), and severity
of symptoms (18) have been chosen as measures of morbidity due to the common cold for Fig. 1B.
 The probability that the distribution of results in Fig. 1B was due to chance was calculated with the formula for
binomial distribution. Provided that the vitamin C and placebo groups are well matched, and that vitamin C does
not affect the common cold, a vitamin group has a 50% probability of showing an increase and a 50% probability
of showing a decrease in morbidity, when compared with a placebo group. Consequently, the probability that all
21 groups, purely by chance, experienced a decrease in morbidity is (0.5)21 = 0.0000005. However, this is a very
conservative estimate of the statistical significance of all the evidence, since several studies have found a
statistically significant difference (p < 0.05) between vitamin and placebo groups (25). The probabilities of individual
studies could be combined by using Fisher's method (26), but it would not be worthwhile, since the null hypothesis that
vitamin C does not differ from placebo, can already be rejected by the simple binomial distribution analysis.
3RESULTS AND DISCUSSION
No marked effect on incidence
Vitamin C has no marked effect on the incidence of the common cold (Fig. 1 A). The
mean decrease in incidence has been –9%. 10 study groups out of 21 found a decrease in
incidence  (–7% and over), while 8 groups found no effect on incidence (range –3%
to +2%) and 3 groups found an increase in incidence (+9% and over). Apart from
4 studies, all the results are quite symmetrically grouped around zero. Of the 4 outliers,
2 contained fewer than 25 subjects (16, 22), the third was poorly described and not
published in a regular scientific forum (11), and the fourth was the only non-double-
blind study of the entire group (6). It is noteworthy that the studies with the largest
numbers of subjects have not shown any consistent decrease in incidence (black bars in
Fig. 1 A). If the results are weighted with the number of subjects used in each study, the
mean change in incidence becomes quite insignificant (–4%). Thus, the studies do not
support the practice of regular ingestion of vitamin C with the purpose of reducing the
incidence of the common cold in the general population.
 It is possible that vitamin C reduces the incidence of common cold in certain
subgroups, but the intervention studies indicate that such subgroups may not be very large
or numerous. Still, it is interesting that 2 studies which found a significant decrease in
incidence were conducted using Canadian military troops undergoing Arctic exercises
(11), and students at a ski school in the Swiss mountains (3), which may suggest that
vitamin C has some effect on the common cold incidence under conditions of great
stress.
Symptoms are alleviated
Each one of the 21 vitamin C groups showed a decrease in the duration or the severity
of symptoms, of common cold episodes (Fig. 1B). The probability that, purely by
chance, none of the vitamin groups would find an increase in morbidity is
extremely small (p =0.0000005). Hence, it is very unlikely that the pattern of results
emerging was due to chance (Fig. 1B). Moreover, the possibility of a systematic bias
seems to be excluded, since all studies, with the exception of a single one (6), were
conducted with the double-blind method. Several of the individual studies, though not
all of them, have observed a decrease in morbidity that has been statistically significant
(5-8, 11, 17-20, 22). Accordingly, there is very strong evidence which indicates that
vitamin C alleviates the symptoms of the common cold. The next question is to assess
the magnitude of the benefit.
Estimation of the benefit
In most of the studies the decrease in morbidity has been between 5% and 35%
 (Fig. 1B). The mean decrease in duration or severity of the common cold has been 23%,
which is not negligible, even though it does not promise total relief from symptoms. A
large number of factors have varied between the studies: types of subject, geographical
location and climate, types of respiratory viruses infecting the subjects, definition of
disease and calculation of the duration and severity, etc. Furthermore, the intake of
vitamin C in the control groups may be an important variable; in some of the studies the
control subjects had received quite large doses of the vitamin in their diet (25). Thus, the
large variation in the effects of vitamin C supplementation may depend on several factors
and, consequently, certain subgroups may benefit much more than the calculated
average.
4Fig. 1. Effect of vitamin C on the common cold.
(A) Relative effect on incidence.
(B) Relative effect on the duration of episodes or on the severity of
symptoms.
A horizontal bar indicates the number of studies recording a
relative change in the vitamin group which falls within the vertical
region of the bar. Black bars indicate the studies in which at least
400 subjects have been used (test and control group combined). A
horizontal line is added to visualize the level of the control group.
Dose of vitamin C
What is the best dose of vitamin C for the treatment of the common cold? Most of the
studies have used 1 g/day. Six study groups were given 2 g/day (7, 9, 10, 18, 20, 22) and
2 groups were given 3 g/day (8, 13). Anderson et al. gave 1 g/day regularly, but increased the
dose to 4 g/day during a cold episode (5). The mean decrease in severity was 19% in studies
that used 1 g/day of the vitamin, and 29% in studies that used 2-4 g/day of the vitamin
during the cold episode (25). This difference suggests that maximal benefit is not obtained
with 1 g/day of the vitamin, even though one must be cautious when comparing the
quantitative results, since there are large experimental variations in the studies.
 Some of the studies have contained 2 or 3 vitamin groups that were given different
doses. In such studies the definition of disease and several other factors have been constant
and therefore the results of the different vitamin groups are comparable. Karlowski et al.
gave 1 group 3 g vitamin C/day regularly, a second group 3 g/day during the cold episode,
and a third group 3 g/day regularly plus 3 g/day during a cold episode (i.e. 6 g/day
during an episode). The average decrease in the duration of symptoms was 5% and 8%
in the 3 g/day groups, and 17% in the 6 g/day group (13). Coulehan et al. gave 1 group of
5children 1 g/day and another group 2 g/day of the vitamin. The decrease in duration of the
episode in these 2 groups was 12% and 29%, respectively (10). Anderson et al. compared
the effect of 4 and 8 g/day when given, in several doses, only on the first day of illness.
The larger dose was consistently more effective when 8 classes of symptoms were
followed to  determine the duration of the episodes (9). Thus, these three studies also
suggest that the maximal benefit is not obtained with 1 g/day of the vitamin.
 Certain physicians have treated their common cold patients with doses still larger than
those used in the intervention studies (27, 28). Cathcart observed that patients with common
cold infection can ingest over 30 g/day of vitamin C without getting diarrhea, in contrast to
healthy subjects who get diarrhea with 4–15 g/day (28). Based on his observations, Cathcart
has proposed that the best dose may be one that is slightly smaller than the dose that causes
stomach problems. He suggests that the dose is first increased to a level that causes minor
stomach ailments, in order to find the upper limit, and thereafter smaller doses are used for
therapy (28).
Placebo effect does not explain the results
It has been suggested that the effect of vitamin C on the common cold could be due to the
placebo effect (29). This suggestion was based on the study by Karlowski et al., in which the
subjects who could correctly identify vitamin C reported, on average, greater benefit from the
vitamin than those who could not identify it (13). In this study the placebo consisted of
lactose, which could easily be distinguished from ascorbic acid by taste. However, it has been
explicitly reported in a number of studies that the placebo tablets were indistinguishable from
the vitamin C tablets (4, 5, 7, 9, 10, 12, 14, 15, 17-20). It is unlikely that the placebo effect
could explain the benefits observed in these studies. Furthermore, provided that vitamin C
does afford some benefit, it is probable that certain subjects can identify whether they get the
vitamin or the placebo on the basis of the physiological effects. For example, Asfora initiated
a double-blind study to test the effect of 6 g/day of vitamin C on the common cold, but
subjects receiving the vitamin could be identified due to their clinical progress (30).
Physiological effects of vitamin C
The beneficial effects of vitamin C against the common cold may be caused by its antioxidant
properties (25). Vitamin C is one of the major biological antioxidants (31). It appears that
neutrophils play a significant role in producing the symptoms of the common cold (32);
in an infection they release large amounts of oxidizing compounds that are toxic to other cells
(33-35). Activation of neutrophils promotes an efficient consumption of extracellular
vitamin C, which suggests that high concentrations of the vitamin may provide protection
against the harmful effects of the oxidants released (36). Furthermore, a common cold
episode causes a significant decrease in vitamin C concentration in leukocytes, and this
decrease can be prevented by giving the subjects 6 g/day of the vitamin (37).
 It is a common assumption that the only physiological role of vitamin C is to prevent
scurvy. For example, the purpose of the nutritional recommendation for vitamin C (60 mg/
day) is the prevention of deficiency (25, 38-42). However, the diet of our ancestors contained
0.4–2 g/day of vitamin C (40, 43, 44), which indicates that such amounts are not unfamiliar
to human physiology, i.e. they are not pharmacological. Furthermore, the nutritional
recommendations are based on the concept of 'nutrient need', which appears to lack a sound
biochemical basis (41, 42). Vitamin C is a cheap and safe nutrient; several of the suspected
side effects of fairly large amounts are unfounded (40, 45, 46). For example, none of the
intervention trials has revealed any significant side effects of the vitamin (3-22). Further-
more, in a recent epidemiological study the men who had been taking vitamin C supple-
ments, on their own initiative, had a standardized mortality rate 30% lower than the
control group (47). Accordingly, there are good reasons for reconsidering the potential
role of vitamin C in the treatment of the common cold.
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